Head to head

Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes

BMJ 2007; 334 doi: 10.1136/bmj.39202.399942.AD (Published 10 May 2007)
Cite this as: BMJ 2007;334:982

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Scott M Grundy, professor
  1. Center for Human Nutrition, Departments of Clinical Nutrition and Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9052, USA
  1. scott.grundy@utsouthwestern.edu

    Women in western countries are more likely to die from heart disease than from cancer. Scott M Grundy argues that the risks make preventive treatment essential, but Malcolm Kendrick believes the evidence of benefit is not strong enough

    Primary and secondary trials show that cholesterol lowering drugs reduce the risk of cardiovascular disease events in men.1 2 Secondary prevention trials in women with established cardiovascular disease also show a reduction in risk.3 4 5 Meta-analyses also show that when all women with or without cardiovascular disease are combined, cholesterol lowering treatment produces benefit.6 7

    Some investigators nevertheless argue that women without cardiovascular disease should not be given cholesterol lowering drugs because of insufficient evidence from primary prevention trials in women.8 They speculate that women with and without cardiovascular disease respond differently to the drugs; if true, women may not respond to treatment even when they have the same level of risk as men who do benefit.1 2 This speculation discounts prospective studies showing that raised cholesterol …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL